Puma Biotechnology, Inc. (PBYI)
| Market Cap | 383.61M |
| Revenue (ttm) | 228.37M |
| Net Income (ttm) | 31.11M |
| Shares Out | 50.88M |
| EPS (ttm) | 0.61 |
| PE Ratio | 12.36 |
| Forward PE | 30.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 227,757 |
| Open | 7.53 |
| Previous Close | 7.51 |
| Day's Range | 7.50 - 7.73 |
| 52-Week Range | 2.85 - 7.90 |
| Beta | 1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas... [Read more]
Financial Performance
In 2025, Puma Biotechnology's revenue was $228.37 million, a decrease of -0.91% compared to the previous year's $230.47 million. Earnings were $31.11 million, an increase of 2.75%.
Financial StatementsNews
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call on May 7 at 1:30 p.m. PT, following release of its first quarter 2026 financial results.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2026, the Compensation Committee of Puma's Board of Directors approved th...
Puma Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
NERLYNX revenues and patient uptake continue to grow, with strong 2026 guidance and profitability focus. Alisertib advances in phase II trials for breast and lung cancer, with interim data expected in 2026 and a biomarker-driven strategy for potential accelerated approval. Patent protection remains robust, and financial discipline is emphasized.
Puma Biotechnology Earnings Call Transcript: Q4 2025
Q4 2025 saw strong revenue growth, with NERLYNX net product revenue and royalties both rising significantly. Clinical trials for alisertib are ahead of schedule, and full-year profitability was achieved for the third consecutive year.
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its 4Q-2025 earnings release on Feb. 26 and followed with a conference call to review results.
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO & President Alan Auerbach will provide a corporate overview at the TD Cowen Health Care Conference on March 2 at 2:30 pm ET.
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its fourth quarter and full year 2025 results, followed be a conference call, after the close on Feb. 26, 2026.
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology was added to the Nasdaq Biotechnology Index effective after the close of trading on Dec. 19, 2025.
Puma Biotechnology Earnings Call Transcript: Q3 2025
Q3 2025 saw net product revenue rise sequentially to $51.9M, with U.S. Nerlynx sales up and demand growth in key channels. Net income improved, and full-year guidance was raised for both revenue and profit, while R&D spending is set to increase due to faster trial enrollment.
Puma Biotechnology Reports Third Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On 11/6/26, Puma Biotechnology issued its financials for Q3-2025 and hosted a conference to discuss operating results.
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue financials and host a conference call on Nov. 6, 2025 to discuss its results for the third quarter of 2025.
Puma Biotechnology Transcript: H.C. Wainwright 27th Annual Global Investment Conference
NERLYNX continues to drive revenue growth, supported by improved dosing strategies and global partnerships. Alisertib advances in phase 2 trials for breast and lung cancers, with strong biomarker-driven potential and rapid enrollment. Interim data from key studies are expected by late 2025.
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
LOS ANGELES--(BUSINESS WIRE)--On 9/8/25, Puma Biotechnology CEO and President Alan Auerbach will present a company overview at the H.C. Wainwright Global Investment Conference.
Puma Biotechnology Earnings Call Transcript: Q2 2025
Q2 2025 saw strong revenue and net income growth, driven by increased NERLYNX sales and higher demand, especially in the specialty distributor channel. Clinical trials for alisertib are progressing ahead of schedule, and full-year guidance was raised for both revenue and net income.
Puma Biotechnology Reports Second Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--On 8/7/2025, Puma Biotechnology issued 2Q-2025 earnings results and followed with a conference call to discuss quarterly and year-to-date results.
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second quarter of 2025.
Puma Biotechnology Earnings Call Transcript: Q1 2025
Q1 2025 net product revenue was $43.1M, down sequentially due to inventory drawdown, with net income at $3M. FY 2025 guidance anticipates $192–$198M in net product revenue and $23–$28M net income. Clinical pipeline advances and new global partnerships support future growth.
Puma Biotechnology Reports First Quarter Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today an...
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov...
Puma Biotechnology Transcript: TD Cowen 45th Annual Healthcare Conference
NERLYNX continues to generate stable revenue with improved tolerability and strong U.S. and international market presence, while alisertib advances in phase II trials targeting biomarker-defined cancer subgroups. Multiple interim data readouts are expected in 2025.
Puma Biotechnology Earnings Call Transcript: Q4 2024
Q4 2024 revenue reached $59.1M, with NERLYNX net product revenue at $54.4M and net income at $19.3M. FY 2025 guidance projects flat product revenue, lower royalties due to China, and net income of $23–28M. Inventory build and regulatory approvals in new markets impacted results.